Skip to main content

Table 2 Affinity toward SST2 and SST5 of all four natGa-DOTA-conjugates compared to reference somatostatin analogs

From: A new 68Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting

Compounds SST2 SST5
IC50, nM (95% CI) IC50, nM (95% CI)
Somatostatin-14* (1) 0.11 (0.08–0.15) 0.35 (0.22–0.55)
natGa-DOTA-ST8950 0.32 (0.20–0.50) 1.9 (1.1–3.1)
natGa-DOTA-ST8951 7.5 (5.2–11) 24 (14–43)
natGa-DOTA-TATE 0.15 (0.11–0.19) 69 (28–168)
natGa-DOTA-NOC 0.70 (0.50–0.96) 3.4 (1.8–6.2)
ST8950 (1) 0.28 (0.19–0.42) 0.77 (0.48–1.2)
Octreotide (1)** 0.24 (0.12–0.48) 17 (12–24)
Pasireotide (1)** 3.1 (2.0–4.9) 0.20 (0.11–0.35)
  1. Experiments were performed in 3 to 5 separate sessions in duplicate
  2. *Somatostatin-14 is the natural ligand and was used as control
  3. **Octreotide and pasireotide were used for comparison, additionally to natGa-DOTA-TATE and natGa-DOTA-NOC
  4. (1)From [25]